1. Home
  2. VGZ vs NERV Comparison

VGZ vs NERV Comparison

Compare VGZ & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$2.18

Market Cap

295.7M

Sector

N/A

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.81

Market Cap

301.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
NERV
Founded
1983
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
295.7M
301.6M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
VGZ
NERV
Price
$2.18
$4.81
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$3.75
$10.50
AVG Volume (30 Days)
1.4M
133.0K
Earning Date
05-12-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$1.57
52 Week High
$3.13
$12.46

Technical Indicators

Market Signals
Indicator
VGZ
NERV
Relative Strength Index (RSI) 46.60 41.02
Support Level $2.02 $3.69
Resistance Level $2.43 $5.61
Average True Range (ATR) 0.14 0.44
MACD -0.02 0.01
Stochastic Oscillator 28.92 37.98

Price Performance

Historical Comparison
VGZ
NERV

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: